Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DHQ9S3
|
|||
| Drug Name |
AMG 256
|
|||
| Drug Type |
Protein
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 21 receptor (IL21R) | Target Info | Agonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Inflammatory bowel disease (IBD) | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| IL5 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04362748) Study of AMG 256 in Adult Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Amgen. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.